We randomly assigned patients ( 1:1 ; stratified by active hepatitis C virus infection and previous treatment ; computer-generated random number sequence ) to dual treatment with oral atazanavir ( 300 mg once daily ) and ritonavir ( 100 mg once daily ) plus lamivudine ( 300 mg once daily ) or triple treatment with oral atazanavir ( 300 mg once daily ) and ritonavir ( 100 mg once daily ) plus two nucleos ( t ) ide reverse transcriptase inhibitors at the discretion of the investigators .